Therapeutic product candidates

Factor VIII Intolerance

Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the blood in response to any type of injury or surgery.

The control of bleeding in haemophilia A requires regular injections of factor VIII. The development of inhibitors, (antibodies) to FVIII, remains the biggest challenge in the treatment of haemophilia A and this occurs in around 30-50% of haemophilia A patients. The development of inhibitors is due to loss of tolerance by the immune system to factor VIII sharply decreasing the efficacy of factor VIII and rendering the protein replacement treatment ineffective.

Apitope has developed a potential first in class antigen specific immunotherapy (ATX-F8-117) which has shown suppression of inhibitor development in relevant experimental models. ATX-F8-117 has clinical trial approval and is ready to enter the clinic. The efficacy of this approach reveals how apitopes could be used to prevent anti-drug antibodies (ADAs) against other therapeutics such as enzyme replacement therapies and monoclonal antibodies